Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

Published:2007-10-08 Issue:11 Volume:40 Page:1007-1017
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Gisselbrecht C,Bethge W,Duarte R F,Gianni A M,Glass B,Haioun C,Martinelli G,Nagler A,Pettengell R,Sureda A,Tilly H,Wilson K

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1705868.pdf

Reference58 articles.

1. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006; 12: 1–30.

2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

3. Ladetto M, Ricca I, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: results from a multicenter randomized GITMO trial. Blood 2005; 106, abstract 675.

4. Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben Bassat I et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457–464.

5. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383–388.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The international reference system for pure β-particle emitting radionuclides: an investigation of the reproducibility of the results;Metrologia;2020-04-27

2. Radioimmunotherapy in the Transplant Setting;Clinical Applications of Nuclear Medicine Targeted Therapy;2018

3. Reactor-Produced Therapeutic Radionuclides;Radiopharmaceuticals for Therapy;2016

4. Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma;The Korean Journal of Hematology;2012

5. Diagnosis and treatment of follicular lymphoma;Swiss Medical Weekly;2011-08-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3